Log in to your Inderes Free account to see all free content on this page.

Nanexa

1.87 SEK

+2.74 %

Less than 1K followers

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+2.74 %

+5.88 %

-21.67 %

-10.64 %

-13.33 %

-26.01 %

+7.71 %

-86.46 %

-77.12 %

Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.

Market cap

297.04M SEK

Turnover

398.24K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19.2.

2026

Annual report '25

29.4.

2026

Interim report Q1'26

27.8.

2026

Interim report Q2'26

All

Press releases

3rd party

ShowingAll content types

Third party research11/7/2025, 8:58 AM

Nanexa: Intensified focus on deals amid growing funding pressure - Emergers

Nanexa’s Q3 report underscores a pivotal moment for the company. While interest in its PharmaShell technology remains strong, with advanced business discussions ongoing and an extended evaluation agreement in a multi-billion-dollar indication, the financial...

Press release11/7/2025, 7:00 AM

Emergers: Equity Research | NANEXA: Intensified focus on deals amid growing funding pressure

Regulatory press release11/6/2025, 7:00 AM

Nanexa publishes interim report for January-September 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release10/16/2025, 6:25 AM

Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

Regulatory press release10/1/2025, 10:40 AM

Nanexa AB changes Certified Adviser to Tapper Partners AB

Press release9/22/2025, 6:00 AM

Nanexa receives Japanese patent approval for specific PharmaShell structure

Third party research8/28/2025, 6:09 AM

Nanexa: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap - Emergers

Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with Phase I data showing once-monthly liraglutide exposure over 36 days without significant gastrointestinal side effects. The company also gained industry...

Press release8/28/2025, 6:00 AM

Emergers: Equity Research | NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap

Regulatory press release8/27/2025, 5:00 AM

Nanexa publishes interim report for January-June 2025

Press release8/8/2025, 8:43 AM

Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market

Press release6/24/2025, 6:00 AM

Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago

Press release6/3/2025, 1:10 PM

Nanexa Highlights NEX-22 and PharmaShell® During an Intensive Period of International Exposure

Press release5/23/2025, 7:15 AM

All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study

Regulatory press release5/15/2025, 1:45 PM

Bulletin from Nanexa’s Annual General Meeting

Press release5/8/2025, 11:06 AM

Nanexa Receives Approval for Late Breaking Abstract at ADA Congress in Chicago in June

Third party research5/7/2025, 7:23 AM

Nanexa: Clinical milestones align ahead of phase Ib/II and licensing push - Emergers

Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 project, with preliminary PK data from the final dose cohort confirming a dose-dependent profile. Management now targets treatment of the first patient in ...

Press release5/7/2025, 6:00 AM

Emergers: Equity Research | NANEXA: Clinical milestones align ahead of phase Ib/II and licensing push

Regulatory press release5/6/2025, 6:15 AM

Nanexa publishes interim report for January-March 2025

Regulatory press release5/5/2025, 7:35 PM

Nanexa and Applied Materials terminates collaboration

Press release5/5/2025, 9:55 AM

Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.